IDEAYA begins Phase 1/2 Part 2 monotherapy expansion of IDE892 in MTAP-deleted pancreatic, lung cancers

• IDEAYA Biosciences initiated Part 2 monotherapy expansion in its Phase 1/2 trial of IDE892 in MTAP-deleted pancreatic cancer, NSCLC.
• No clinical results were presented; the update focused on trial progress and expansion start.
• Expansion followed dose escalation that reached projected target drug exposure levels; maximum tolerated dose has not been reached.
• Combination dose escalation continues for IDE892 with IDE397 in MTAP-deleted NSCLC, pancreatic cancer; pan-RAS combination first-patient-in targeted H2 2026.
• Program positions IDE892 as a potential backbone for MTAP-deleted tumors, an area with no approved therapies and meaningful prevalence in pancreatic cancer, NSCLC.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEAYA Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF11839) on July 27, 2026, and is solely responsible for the information contained therein.